MedTrace Logo

Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo

NCT00915876 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-12-02

Study results available
· View outcomes & findings →

Summary

This research is studying how Vitamin D may affect blood vessels reaction to stress and blood levels of substances that may increase blockages in the blood vessels in chronic kidney disease (CKD) patients. Blood vessel health is worsened in CKD and some studies have shown that Vitamin D improves blood vessel health. The type of Vitamin D being used in this study (paricalcitol) is Food and Drug Administration (FDA) approved to treat high parathyroid hormone levels. The purpose of this study is to find out if paricalcitol has other benefits beyond its ability to lower parathyroid hormone levels such as improving the blood vessels reaction to stress and decreasing blood levels of substances that may increase blockages in the blood vessels.

Conditions

Interventions

DRUG

Paricalcitol

paricalcitol 1 mcg QD x 8 weeks

DRUG

Placebo

Placebo for Paricalcitol 1 mcg QD x 8 weeks

Sponsors & Collaborators

  • Albany College of Pharmacy and Health Sciences

    collaborator OTHER

  • Amy Barton Pai

    lead OTHER

Principal Investigators

  • Amy Pai, Pharm.D. · Albany College of Pharmacy and Health Sciences

  • Amy Pai, PharmD · Albany College of Pharmacy and Health Sciences

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00915876 on ClinicalTrials.gov